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Background: We measured and assessed ways to reduce the secondary neutron dose from a system for proton
eye treatment.
Methods: Proton beams of 60.30 MeV were delivered through an eye-treatment snout in passive scattering mode.
Allyl diglycol carbonate (CR-39) etch detectors were used to measure the neutron dose in the external field at 0.00,
1.64, and 6.00 cm depths in a water phantom. Secondary neutron doses were measured and compared between
those with and without a high-hydrogen–boron-containing block. In addition, the neutron energy and vertices
distribution were obtained by using a Geant4 Monte Carlo simulation.
Results: The ratio of the maximum neutron dose equivalent to the proton absorbed dose (H(10)/D) at 2.00 cm
from the beam field edge was 8.79 ± 1.28 mSv/Gy. The ratio of the neutron dose equivalent to the proton
absorbed dose with and without a high hydrogen-boron containing block was 0.63 ± 0.06 to 1.15 ± 0.13 mSv/Gy at
2.00 cm from the edge of the field at depths of 0.00, 1.64, and 6.00 cm.
Conclusions: We found that the out-of-field secondary neutron dose in proton eye treatment with an eye snout is
relatively small, and it can be further reduced by installing a borated neutron absorbing material.
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Proton beam therapy and heavy ion therapy are increas-
ingly used because of their excellent dose localization
performance. This high-precision localization is achieved
by the Bragg peak effect, which affords a sharp distal
fall-off in depth dose distribution compared with normal
photon therapy. Proton therapy thus results in high
target conformity and a very low integral dose delivered
to the normal tissue. Although new photon therapy
techniques such as intensity-modulated radiotherapy can
enable dose distribution in a high-dose region compar-
able to that of proton therapy, the latter has the advan-
tage of a low integral dose, which is related to low
complication rates in normal tissue [1,2].* Correspondence: dongho@ncc.re.kr
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reproduction in any medium, provided the orOne area of great interest is the extra dose emitted by
secondary neutrons produced by nuclear interactions
with the material in the beam path during proton and
heavy ion therapy. The amount of the secondary neutron
dose generated from the proton or heavy ion therapy
machines can be dependent on the beam delivery system
because neutron production is highly dependent on the
material in the beam path and on the design of the beam
line. In addition, neutrons have high relative biological
effectiveness (RBE) in that even a small dose of neutrons
can have a large effect on the patient.
Neutron dose equivalents and neutron spectral fluences
delivered outside the radiation field to patients undergoing
proton treatment have been measured as a function of the
lateral distance of the beam axis using a Bonner sphere
and a LiI thermal neutron detector for particular scattered
proton beams [3]. The neutron dose equivalent per proton
absorbed dose in a large-field beam 50 cm from the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mSv/Gy [3]. For eye beams, this value was estimated to be
about 0.02 mSv/Gy at the same distance. In 2009, the
National Cancer Center (NCC) of Korea reported the
secondary neutron doses for craniospinal irradiation
(CSI), hepatocellular configuration (HCC), and pros-
tate beam configuration for proton therapy using an allyl
diglycol carbonate (CR-39) detector [4]. An early eye beam
measurement [5] was also reported in 1998 that measured
the secondary neutron dose inside an Alderson phantom
for the Paul Scherrer Institute (PSI) proton spot beam
with the maximum contribution (6.80 mGy) detected for
a 60-Gy treatment dose. Similar studies have estimated
secondary neutron doses from scattering and spot proton
beam therapy [6-10].
Since 2007, the NCC has treated more than 400 patients
with proton therapy using an Ion Beam Applications
(IBA) PROTEUS 235 proton therapy machine. This pro-
ton system consists of a 230-MeV proton cyclotron, a
beam line, two gantry rooms, and a fixed-beam room. The
cyclotron provides a uniform 230 MeV of proton energy,
and the energy is attenuated to a level appropriate for the
treatment of the patient in the beam delivery system. For
normal eye treatment, the energy degrader initially de-
creases the proton energy at the front of the beam line,
and then, the beam delivery system in the treatment room
ultimately attenuates the proton energy to ~60 MeV,
which provides a range of approximately 3.00 cm. The
fixed-beam room and the gantry room have similar sys-
tems inside except for the beam angle availability. These
two types of treatment rooms are made applicable to eye
treatment by attaching an eye snout, which provides a cir-
cular exit of diameter 4.00 cm for the beam field. The
scattered eye proton beam loses its energy through its
interaction with the material of the beam delivery system,
including the eye snout, which may generate secondary
neutrons. It is therefore important to understand and esti-
mate the quantity of secondary neutrons produced by the
eye beam delivery system.
We measured the secondary neutron dose equivalent
per proton absorbed dose in a proton eye treatment unit
in single scattering mode using a CR-39 neutron detector
[10-16] at the NCC, Korea. We expected that the second-
ary neutrons from the beam delivery system could be
reduced by using a neutron absorber before reaching the
patient’s body. We therefore measured the secondary neu-
tron dose equivalent per proton absorbed dose in a proton
eye treatment unit in the single scattering mode with an
additional high-hydrogen–boron-containing polyethylene
block (SWX207HD5). Using the Geometry and Tracking
(GEANT4, GEANT4 Collaboration) Monte Carlo (MC)
method, we simulated the proton eye beam delivery sys-
tem to determine the distribution of secondary neutron
generation in the beam delivery system.Methods
Neutron dose of the proton eye beam delivery system
In this study, a range of 3.23 cm and a spread-out Bragg
peak (SOBP) of 3.17 cm for the proton beam were used
to cover the target volume of an ocular melanoma or
other eye malignancy with an eye snout [17-19]. The
range was defined as the depth from the water surface
to 90% of the peak position in distal fall-off. The SOBP
was defined as the flatted output region from 90% of the
peak position proximal to 90% of the peak position in
the distal fall-off.
Figure 1 shows a side-view diagram of the measure-
ment set-up. We used a 4.00-cm diameter for the proton
beam field, which was created by a 4.00-cm-diameter
circular, open brass block installed at the end of the eye
snout. The air gap between the end of the eye snout and
the water phantom was 10.00 cm. The proton beams en-
tered the water phantom through a 0.0254-cm-thick
Mylar window to reduce the proton range shift effect
owing to the thickness of wall of the water phantom on
the beam path.
The size of the eye beam field at the end of beam pipe
was approximately 2.5 cm, and proton beam field size
become broadened due to interactions with the materials
in the beam delivery system such as the ion chambers,
first scatter, and the range modulator (RM). The proton
beam size between the ion chamber #3 and the front of
the eye snout was measured to be 18.00 × 19.80 cm2
by using electron beam tomography (EBT) film with
10 × 10 cm2 of collimation. The difference between
the XY collimator’s opening size and the measured
field size is due to the distance between the film pos-
ition and the collimator along the beam axis. In
addition, the measured X and Y field sizes in the EBT
film were different because the positions of the X and
Y collimators along the beam axis are different. In-
clude the XY collimator, most of the materials in the
proton eye beam delivery system, can be a source of
secondary neutrons by interaction with the protons. Fi-
nally, the field size was decreased to 4.00 cm in diameter
by screening the eye snout materials and brass block,
which potentially produces secondary neutrons by nuclear
interaction.
Figure 2 shows the EBT film measurements at each
measuring position. The eye snout consists of brass,
stainless steel, and other minor materials with brass be-
ing the dominant material.
CR-39 (Fukuvi Chemical Industry Co., Ltd., Fukui,
Japan) was used to estimate the neutron dose produced
by the eye beam delivery system in this study. The size of
the sensitive area of the CR-39 detector was 46.8 mm2 in
a 6.9-mm square. The thickness of the detector was 0.9
mm. The chemical composition of the CR-39 plastic track
detector was C12H18O7 with a density 1.3 g/cm
3. When
Figure 1 Setup layout. Diagram of the measurement set-up.
Figure 2 Secondary neutron dose at proton eye snout. View of the Geant4 simulation for the NCC proton eye beam delivery system. Most
secondary neutrons were generated at the range modulator, the eye snout, and the water phantom. In the figure, three EBT film measurements
at three different points are shown for the proton beam: (a) exit position of the beam pipe, (b) interim position between the eye snout and ion
chamber 2, (c) exit position of eye snout. The proton beam was spread out in the lateral direction by interaction with materials in the beam path.
We measured the lateral diameters of the proton beam at each position by using EBT film. From the exit of beam pipe to the front of the eye
snout, the diameter of the beam cross section increased from (a) 2.5 cm to (b) 19 cm and then decreased to (c) 4 cm by the eye snout.
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chemical bonds of the polymer and produce damage trails
from recoil protons. The damage trails or tracks can be
measured using an optical microscope after suitable
chemical etching, electrochemical etching, or both. By
counting a statistically significant number of tracks on the
surface of the detector within a given area, the absorbed
dose or dose equivalent value can be estimated.
The detectable energy with CR-39 ranges from 100
KeV to 20 MeV, which fully covers most of the second-
ary neutrons in proton therapy [15,16]. Therefore, the
dose response of the relatively fast neutrons with ener-
gies of more than 20 MeV and the scattered neutrons
with energies of less than 100 KeV are relatively low
compared to that of relatively low neutrons with ener-
gies ranging from the 100 KeV to 20 MeV. The relatively
fast neutrons are produced dominantly by the direct
process at the position closer to the beam axis; therefore,
the inefficiency of the detector can affect the measure-
ment at near the field edge. However, we evaluated the
relatively fast portion of the neutrons using the MC
simulation. The relatively fast portion of the neutrons is
less than 3% of the total neutron energy spectrum from
the MC simulation study. The uncertainty due to the
inefficiency of the CR-39 for scattered neutrons still ex-
ists in this study. In addition, primary protons, which
have higher energy, will not produce tracks in the de-
tector, because their energies are above the threshold of
the detector.
To estimate the external neutron dose produced by
the eye beam delivery system, CR-39 detectors were
installed on the surface of the water phantom wall at
distances of 2.00 cm, 4.00 cm, 6.00 cm, and 8.00 cm
from the edge of the field (group A). To measure the
neutron dose at the target and in normal tissue, CR-39
detectors were installed at depths of 1.64 cm and 6.00 cm
at the same distances from the field edge (groups B and C,
respectively).
Neutron dose with SWX207HD5
To determine the change caused by the secondary
neutron dose, a 3.00-cm-thick piece of SWX207HD5
self-extinguishing borated polyethylene (Shieldwrex™,
Rio Rancho, New Mexico, USA) neutron shielding with a
4.00-cm hole was installed 70 cm from the isocenter.
SWX207HD5 is composed of 5.50% boron and 5.70%
hydrogen, and it has characteristics suitable for neutron
attenuation. The macroscopic thermal neutron cross-
section is 0.41 cm−1, and the gamma and neutron resist-
ance is 5.0 × 106 Gy and 2.5 × 1017 n/cm2, respectively.
The recommended temperature limit is 93.30°C, and the
solubility in water is negligible. In addition, this material is
a better attenuation material for a proton beam compared
with normal polymethyl-methacrylate (PMMA) because ithas a higher density (1.60 g/cm3) than normal PMMA
(1.18 g/cm3). We expected that a normal eye treatment
beam, which has less than a 4.00-cm range, could be
stopped by using a 3.00-cm-thick piece of SWX207HD5.
CR-39 detectors were installed on the surface (group A),
and at depths of 1.64 cm (group B) and 6.00 cm (group C)
in the water phantom at various distances from the beam
field edge.
Neutron dose equivalent to the proton absorbed dose
The neutron dose equivalent to the proton absorbed
dose was evaluated by comparing each CR-39 measure-
ment and the output measurement of the 0.015 cc pin-
point chamber (type 31014 PTW: Freiburg, Germany)
with a DOSE1 electrometer chamber (IBA Dosimetry:
Schwarzenbruck, Germany) at the mid-depth of the
SOBP (1.64 cm) in the water phantom. The CR-39
detectors were calibrated at the Korea Atomic Energy
Research Institute with a D2O-moderated
252Cf neutron
source. The calibration room is 8 m long, 6 m wide, and
6 m high. The source and detector were placed at a
height of 2.9 m near the center of the room. The dose
equivalent H was calculated for moderated and un-
moderated neutron spectra based on the data provided
in International Commission on Radiological Protection
(ICRP) Publication 74. We used CR-39 detectors cali-
brated as H*(10) dose equivalents using 252Cf from the
Korea Atomic Energy Research Institute. By cross-
checking dose measurements between the independently
calibrated CR-39 detectors and a 3He Swendi-2 neutron
detector [15,20,21] located 100 cm from the isocenter in
the vertical direction to the beam axis, we found that
the measurements recorded by the two detectors were
concordant within 14%. This indicates that the CR-39
detectors are useful dosimetry tools for measuring neu-
tron dose. For cross-checking, we chose a 22-cm range
with a 5-cm SOBP.
Monte Carlo simulation
In 2010, the NCC [22] reported on the GEANT4
MC-based simulation for the IBA PROTEUS235 pas-
sive proton beam delivery system using a modulation
wheel at the NCC. In that report, they introduced the fun-
damental class, which is an object for constructing the
geometry and materials of the proton beam delivery sys-
tem including the eye snout. The NCC presented the user
physics list of the GEANT4 and the validation of a pristine
Bragg peak and an SOBP in the report. By using the same
tool, the proton eye beam delivery system was simulated
as shown as Figure 2. To calibrate from the exit hall of the
beam pipe to the end of the snout, 110 logical volumes
were constructed and assigned to each component of the
eye beam delivery system. The portion of secondary
neutrons generated at each sub-part of the eye beam
Kim et al. Radiation Oncology 2013, 8:182 Page 5 of 9
http://www.ro-journal.com/content/8/1/182delivery system when secondary neutrons entered the
26 × 26 × 20 cm3 water phantom from the incident
protons was calculated to find the major contribution
to the neutron dose. To find the neutron-generated
component in the eye beam delivery system, the ver-
tex position and parent information of each neutron
track that entered the water phantom were stored.
For this MC study, 1,152,112,300 neutron events and
1,022,850,920 proton events were generated and simu-
lated for the proton eye beam delivery system with and
without the SWX207HD5 block inside the eye snout.
Figure 3 shows the percentage depth dose distributions
of both the MC calculation and measurements. The
range difference between the measurement and the MC
calculation was 1 mm. The chamber measurement for
the proton eye beam percentage depth dose was mea-
sured from a depth of 2.7 cm to account for the 1.7-cm
wall thickness of the 3D water phantom and the 1-cm
margin of safety in the chamber to avoid collision be-
tween the chamber and the wall of the water phantom.
Results
Monte Carlo calculation
Using the GEANT4 MC method, we simulated the pro-
ton eye beam delivery system at the NCC. Figure 4
shows the calculated neutron energy spectrum binned in
1 MeV intervals of the eye proton delivery system. The
portion of neutrons in the total neutron energy
spectrum with energies greater than 20 MeV was 2.3%.
Therefore, the inefficiency caused by the limitation of
the CR-39 detector for high-energy neutron detection
was relatively small. In the present study, the data did
not include the dose from neutrons with energies higherFigure 3 SOBP of the proton eye beam delivery system. Comparison o
measurement (circle) and Monte Carlo result (cross). The range and SOBP wthan 20 MeV. Figure 5 shows the portion of secondary
neutrons generated at each sub-part of the eye beam
delivery system when secondary neutrons from 66,797
incident protons entered the 26 × 26 × 20 cm3 water
phantom. From the simulation study, we found that
about 60% of the secondary neutrons are generated at
the eye snout.
Variation in the external field neutron dose equivalent
with distance from the field edge
Table 1 and Figure 6 show the neutron doses equivalent
to the proton absorbed doses at various depths and dis-
tances from the isocenter beam. These measurements
were taken outside the 4-cm-diameter primary field. The
neutron dose equivalents to the proton absorbed doses
(H(10)/D) (mSv/Gy) measured 2–8 cm from the primary
field edge ranged from 0.51 ± 0.02 to 8.79 ± 1.28 at the
surface (group A), from 0.37 ± 0.02 to 5.60 ± 0.13 at a
depth of 1.64 cm (group B), and from 0.16 ± 0.01 to
0.20 ± 0.03 at a depth of 6 cm (group C). Although a
previous study reported a neutron dose equivalent of
0.02 mSv/Gy with an ocular beam at distances greater
than 20.0 cm [3], it is difficult to compare these results
directly with ours because of differences in the measure-
ment positions and the eye-snout systems. Nevertheless,
the values were similar.
Change in neutron dose with SWX207HD5
Table 1 and Figure 6 show the neutron doses equivalent
to the proton absorbed doses at various depths and
distances from the isocenter for the proton beam with
and without SWX207HD5. The external field neutron
doses equivalent to the proton absorbed doses (mSv/Gy)f the SOBP of the proton eye beam delivery system between the
ere 3.23 and 3.17 cm, respectively.
Figure 4 Energy distribution of the secondary neutrons calculated by the Geant 4 Monte Carlo simulation. Calculated neutron energy
spectrum binned in 1 MeV intervals on eye proton delivery system.
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phantom were 8.79 ± 1.28 and 5.56 ± 0.53 at 2.00 cm from
the primary field edge, respectively. The ratio of the neu-
tron dose equivalent to the proton absorbed dose with
and without a high-hydrogen–boron-containing block on
the surface was 0.63 ± 0.06 at 2.00 cm from the edge of
the field. The ratio of the neutron dose equivalent to the
proton absorbed dose with and without a high hydrogen-
boron containing block at depths of 0.00 cm, 1.64 cm, and
6.00 cm was 0.63 ± 0.06, 0.42 ± 0.04, and 1.15 ± 0.13, re-
spectively, at 2.00 cm from the edge of the field. At a
depth of 6.00 cm, the ratio of the neutron dose equivalentFigure 5 Portions of secondary neutron generation in the
beam delivery system. View of the portions of secondary neutron
generation at each sub-part inside the eye treatment beam
delivery system.to the proton absorbed dose with and without a high
hydrogen-boron containing block was higher than 1.0
with a large error because of the relatively small magni-
tude of the dose after distal fall-off of the proton beam.
We found the maximum external neutron dose equivalent
to the proton absorbed dose without SWX207HD5 was
60% higher than that with SWX207HD5 (Figure 6).
Discussion
When the 2.50-cm-diameter core of the eyebeam is
injected from the nozzle beam pipe into beam delivery
system in the fixed-beam room, the eyebeam is spread
out to 19.80-cm diameter owing to scattering by the ma-
terials in the beam path as shown as Figure 2. Subse-
quently, the diameter of the eye beam is reduced to 4.00
cm at the end of the eye snout. Except for the 4.00-cm
opening, the proton eye beam is stopped by the eye
snout material, and secondary neutrons may be pro-
duced when the eye beam passes through the ion cham-
bers, range modulator, mirror, collimators, and/or the
eye snout. Nuclear interactions between the protons and
the materials in the beam path may produce secondary
neutrons when proton beams are used for patient treat-
ment or quality assurance testing.
Figure 6 shows that the external field neutron doses
equivalent to the proton absorbed doses (mSv/Gy)
ranged from 8.79 ± 0.16 mSv/Gy at 2.00 cm to 0.51 ± 0.02
mSv/Gy at 8.00 cm displacement from the field edge on
the surface of the water phantom. These values are
comparable to previously determined values of approxi-
mately 0.03 mSv/Gy at 25.00 cm and 0.02 mSv/Gy at
50.00 cm displacement from the isocenter by Massachusetts
Table 1 External neutron dose
Group Depth [cm] SWX207 Distance from beam edge [cm]
2.00 4.00 6.00 8.00
A 0.00 W/O 8.79 ± 1.28 0.90 ± 0.08 0.58 ± 0.03 0.51 ± 0.02
W/ 5.56 ± 0.53 0.52 ± 0.11 0.38 ± 0.04 0.35 ± 0.01
Ratio 0.63 ± 0.06 0.58 ± 0.13 0.66 ± 0.08 0.67 ± 0.02
B 1.64 W/O 5.60 ± 0.13 0.49 ± 0.06 0.32 ± 0.02 0.37 ± 0.02
W/ 2.34 ± 0.20 0.25 ± 0.02 0.22 ± 0.02 0.25 ± 0.01
Ratio 0.42 ± 0.04 0.51 ± 0.07 0.69 ± 0.08 0.68 ± 0.03
C 6.00 W/O 0.20 ± 0.03 0.17 ± 0.03 0.15 ± 0.02 0.16 ± 0.01
W/ 0.23 ± 0.01 0.16 ± 0.02 0.16 ± 0.02 0.13 ± 0.01
Ratio 1.15 ± 0.13 0.94 ± 0.20 1.07 ± 0.18 0.82 ± 0.06
External neutron doses (H(10)/D (mSv/Gy)) at various depths and distances from the beam isocenter with and without SWX207HD5 in single-scattering mode.
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dosimetry was used to at MGH determine that the exter-
nal field neutron dose equivalent value ranges from 0.60
mSv/Gy at 2.50 cm to 0.07 mSv/Gy at 10.00 cm displace-
ment from the field edge for a range of 2.70 cm and an
SOBP beam of 2.50 cm with a 2.80 cm pre-collimation
field diameter [12]. In spite of differences in the eye snout
design and the collimator field size, their results are
relatively consistent with our findings when compar-
ing the large field observed in the proton double-
scattering mode or by a spot beam [3,4]. It is difficult
to compare these earlier results directly with ours be-
cause the neutron dose depends strongly on the ma-
terial in the beam path. Thus, the results will dependFigure 6 Secondary neutron dose at the proton eye snout. External ne
according to the distance at the surface, in the middle of the SOBP (1.64 c
show the results at the surface without the SWX207HD5. Rectangles show
results at a depth of 1.64 cm without the SWX207HD5. Plus signs show the
the results at a depth of 6 cm without the SWX207HD5. Crosses show theon the beam delivery system, including the eye snout
design. Moreover, the measurement positions used in
the two studies were quite different [3,4].
To assess the neutron dose [10,11] created by the
interaction between the proton beam and the patient’s
body, we measured the neutron dose equivalent to the
proton absorbed dose for the lateral direction in the
middle of the SOBP (1.64 cm) and after the distal fall-off
(6 cm). As shown in Table 1 (Group B), the neutron doses
equivalent to the proton absorbed doses ranged from 5.60
± 0.13 mSv/Gy at 2.00 cm to 0.37 ± 0.02 mSv/Gy at 8 cm
displacement from the field edge. In addition, the neutron
doses equivalent to the proton absorbed doses at the 6 cm
position after the distal fall-off became non-negligible;utron doses equivalent to the proton absorbed doses (mSv/Gy)
m), and after the distal fall-off (60 cm) in the water phantom. Circles
the results at the surface with the SWX207HD. Triangles show the
results at a depth of 1.64 cm with the SWX207HD5. Diamonds show
results at a depth of 6 cm with the SWX207HD5.
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Neutrons can be attenuated by a two-step procedure.
The first step is to slow the neutrons because high-
energy neutrons do not stop. This requires high-density
materials in the eye beam delivery system for inelastic
collisions, and hydrogenated materials to reduce the en-
ergy of the neutrons. After the neutrons are slowed, they
can be captured by an absorbing material (boron) as a
final step. We found that the SWX207HD5, which con-
tains 5.50% boron and 5.70% hydrogen, can reduce the
neutron dose in our proton eye beam delivery system.
The neutron doses equivalent to the proton absorbed
doses with and without the SXW207HD5 was separated
by more than 2 times the error with an average of about
5 times the error. Moreover, the neutron dose without
the SWX207HD5 was about 60% higher than the neu-
tron dose with the SWX207HD5 when measured 2.00 cm
from the displacement edge as shown in Table 1 (group
A). When the depth was less than the distal fall-off, the
neutron dose without the SWX207HD5 was 46–138%
higher than the neutron dose with the SWX207HD5. For
the neutron dose after distal fall-off, there were no signifi-
cant differences between the cases with and without the
SWX207HD5. It is known that CR-39 has less sensitivity
to low-energy neutrons such as thermal neutrons; how-
ever, the energy weighted neutron dose equivalent[23]
ranged from 5 to 50 KeV from Monte Carlo study is about
1.4% comparing to the energy weighted neutron dose
equivalent for higher energy neutrons. Therefore, the less
sensitivity of the CR-39 to low energy neutron will not
influence to the measurement in this study.
Although, the SWX207HD5 reduced the neutron dose
as described above, secondary neutrons can be gener-
ated in other places in the aperture and the patient’s
body. Neutron generation in the aperture can be re-
duced by changing the aperture material from brass
to SWX207HD5. At 2009, Brenner et al. [24] reported
a reduction of the secondary neutron dose in pas-
sively scattered proton radiotherapy by using an opti-
mized pre-collimator. In his report, the secondary
neutron dose calculated using a Monte Carlo simula-
tion for different pre-collimator materials such as the
brass, tungsten alloy, Cerrobend, nickel, iron, and
SWX207HD5. He reported the collimator-produced
neutron dose can be reduced by using a high-density
polyethylene pre-collimator in spite of the fact that it
lies within the required collimator thickness (195 mm for
235-MeV protons). However, neutron generation in a
patient’s body inside the region of the proton beam field is
not reducible.
In 2008, Fontenot et al. [25] reported the majority of
the effective dose and equivalent dose came from exter-
nal neutrons created in the nozzle. They also showedthat internal neutrons created in the patient contributed
significantly to the equivalent doses in tissue near the
proton treatment field. About 40% of the equivalent dose
from neutrons was contributed by internal neutrons. In
the present study, the ratio of neutron dose equivalent
with SWX207HD5 to without SWX207HD5 on the sur-
face (or middle of the SOBP) measured greater than 1,
which caused by the contribution of internal neutrons to
become relatively lower than the external neutrons cre-
ated in the eye snout. However, the reduction of the
neutron dose equivalent by neutron-shielding material
such as SWX207HD5 is relatively decreased by increas-
ing the contribution of the internal neutrons inside the
phantom at greater depth. Therefore, secondary neutron
generation in the patient’s body in the field region and
its effect on normal tissue will be an important and
interesting issue worthy of further investigation.
Conclusions
We concluded that the secondary neutron dose for a
typical eye treatment beam in the NCC, Korea, ranges
from 0.16 ± 0.01 mSv/Gy to 8.79 ± 1.28 mSv/Gy with the
eye snout system when the displacement from the field
edge ranges from 2.00 cm to 8.00 cm. This finding indi-
cates that the secondary neutron dose is relatively small
when compared with other treatment methods. Thus,
proton therapy for eye treatment will have the advan-
tages of precise target conformity and a low integral
dose with negligible secondary neutron doses. Further-
more, we found that the secondary neutron dose could
be reduced by installing a neutron-absorbing material
such as SWX2007HD5. However, neutron generation in
a patient’s body is not reducible. Therefore, it will be
very important to understand secondary neutron gener-
ation inside a patient’s body and to estimate the prob-
ability of complications in normal tissue induced by
these internal neutrons. In addition, a neutron-absorbing
material can be used to reduce the secondary neutron
doses at other treatment sites by changing the aperture
material from brass to a neutron-absorbing material,
which may result in large neutron doses in craniospinal
irradiation (CSI) [13,14].
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
DWK and DS designed and wrote a first version of the manuscript for this
research. JS provided the GEANT4 Monte Carlo results. WKC, SP, and DOS
provided the clinical support. YKL, SBL, JC, and MY participated in the
measurements and the detector calibrations. All authors read and approved
the final manuscript.
Acknowledgements
This work was supported by a research grant from the National Cancer
Center, Korea (no. 1110600) and General Researcher Program (2012003174)
through the National Research Foundation.
Kim et al. Radiation Oncology 2013, 8:182 Page 9 of 9
http://www.ro-journal.com/content/8/1/182Author details
1Department of Radiation Oncology, Kyung Hee University Hospital at
Gandong, Seoul, Korea. 2Radiation Oncology, University of California, San
Francisco, USA. 3Proton Therapy Center, National Cancer Center, Ilsan, Korea.
4Department of Radiological Science, Korea University, Seoul, Korea. 5Proton
Therapy Center, McLaren Cancer Institute, Flint, MI, USA. 6Department of
Radiation Oncology, Kyung Hee University Medical Center, Seoul, Korea.
7Department of Radiological Science, Jeonju University, Jeonju, Korea.
Received: 10 January 2013 Accepted: 15 July 2013
Published: 17 July 2013References
1. Schneider U, Lomax A, Lombriser N: Comparative risk assessment of
secondary cancer incidence after treatment of Hodgkin's disease with
photon and proton radiation. Radiat Res 2000, 154:382–388.
2. Jiang H, Wang B, Xu XG, Suit HD, Paganetti H: Simulation of organ-specific
patient effective dose due to secondary neutrons in proton radiation
treatment. Phys Med Biol 2005, 50:4337–4353.
3. Yan X, Titt U, Koehler AM, Newhauser WD: Measurement of neutron dose
equivalent to proton therapy patients outside of the proton radiation
field. Nucl Instrum Methods Phys Res, Sect A 2002, 476:429–434.
4. Shin D, Yoon M, Kwak J, Shin J, Lee SB, Park SY, Park S, Kim DY, Cho KH:
Secondary neutron doses for several beam configurations for proton
therapy. Int J Radiat Oncol Biol Phys 2009, 74:260–265.
5. Agosteo S, Birattari C, Caravaggio M, Silari M, Tosi G: Secondary neutron
and photon dose in proton therapy. Radiother Oncol 1998, 48:293–305.
6. Schneider U, Agosteo S, Pedroni E, Besserer J: Secondary neutron dose
during proton therapy using spot scanning. Int J Radiat Oncol Biol Phys
2002, 53:244–251.
7. Polf JC, Newhauser WD, Titt U: Patient neutron dose equivalent exposures
outside of the proton therapy treatment field. Radiat Prot Dosimetry 2005,
115:154–158.
8. Hall EJ: Intensity-modulated radiation therapy, protons, and the risk of
second cancers. Int J Radiat Oncol Biol Phys 2006, 65:1–7.
9. Paganetti H, Bortfeld T, Delaney TF: Neutron dose in proton radiation
therapy: in regard to Eric J. Hall (Int J Radiat Oncol Biol Phys 2006;
65:1–7). Int J Radiat Oncol Biol Phys 2006, 66:1594–1595. author reply 1595.
10. Jarlskog CZ, Paganetti H: Sensitivity of different dose scoring methods on
organ-specific neutron dose calculations in proton therapy. Phys Med Biol
2008, 53:4523–4532.
11. Perez-Andujar A, Newhauser WD, Deluca PM: Neutron production from
beam-modifying devices in a modern double scattering proton therapy
beam delivery system. Phys Med Biol 2009, 54:993–1008.
12. Wroe A, Clasie B, Kooy H, Flanz J, Schulte R, Rosenfeld A: Out-of-field dose
equivalents delivered by passively scattered therapeutic proton beams
for clinically relevant field configurations. Int J Radiat Oncol Biol Phys 2009,
73:306–313.
13. Taddei PJ, Mirkovic D, Fontenot JD, Giebeler A, Zheng Y, Kornguth D,
Mohan R, Newhauser WD: Stray radiation dose and second cancer risk for
a pediatric patient receiving craniospinal irradiation with proton beams.
Phys Med Biol 2009, 54:2259–2275.
14. Kim DW, Shin J, Ahn SH, Lee SY, Shin D, Yoon M, Lee SB, Park SY:
Measurement of the secondary neutron dose generated during proton
beam therapy for craniospinal irradiation. J Korean Phys Soc 2010,
56:1208–1214.
15. Moyers MF, Benton ER, Ghebremedhin A, Coutrakon G: Leakage and
scatter radiation from a double scattering based proton beamline.
Medical physics 2008, 35:128–144.
16. Kim B, Han S, Kwon J, Jun S, Kim J, Lee SB, Shin D: Neutron spectral
measurement at the proton therapy room of the national cancer center
of Korea. J Nucl Sci Technol 2008, Supplement 5:229–232.
17. Goitein M, Miller T: Planning proton therapy of the eye. Medical physics
1983, 10:275–283.
18. Bonnett DE, Kacperek A, Sheen MA, Goodall R, Saxton TE: The 62 MeV
proton beam for the treatment of ocular melanoma at Clatterbridge.
Br J Radiol 1993, 66:907–914.
19. Egger E, Zografos L, Schalenbourg A, Beati D, Bohringer T, Chamot L,
Goitein G: Eye retention after proton beam radiotherapy for uveal
melanoma. Int J Radiat Oncol Biol Phys 2003, 55:867–880.20. Olsher R, Hsu H, Beverding A, Klerk J, Willian H, Vasilik D, Robert T: Wendi:
an improved neutron rem meter. Health Phys 2000, 79:170–181.
21. Corp TE: SWENDI-2 detector technical manual. In WENDI-2 Detector
Technical Manual. City: Thermo Electron Corp; 2003.
22. Shin J, Kim D, Lim Y, Ahn S, Shin D, Yoon M, Park S, Lee S: Monte Carlo
modeling and simulation of a passive treatment proton beam delivery
system using a modulation wheel. J KyPhys Soc 2010, 25:153–163.
23. NCRP: Protection against neutron radiation. NCRP Report 38. Washington, DC:
National Council on Radiation Protection and Measurements; 1971.
24. Brenner DJ, Elliston CD, Hall EJ, Paganetti H: Reduction of the secondary
neutron dose in passively scattered proton radiotherapy, using an
optimized pre-collimator/collimator. Phys Med Biol 2009, 54:6065–6078.
25. Fontenot J, Taddei P, Zheng Y, Mirkovic D, Jordan T, Newhauser W:
Equivalent dose and effective dose from stray radiation during passively
scattered proton radiotherapy for prostate cancer. Phys Med Biol 2008,
53:1677–1688.
doi:10.1186/1748-717X-8-182
Cite this article as: Kim et al.: Secondary neutron dose measurement for
proton eye treatment using an eye snout with a borated neutron
absorber. Radiation Oncology 2013 8:182.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
